Business Standard

Covid-19: Sinovac vaccine shows 78% efficacy in Brazil after data confusion

The protection rate, confirmed by Sao Paulo state officials, was derived from Sinovac's most advanced final-phase trials in Brazil involving about 13,000 participants

Sinovac, Vaccine
Premium

Sinovac’s CoronaVac vaccine was 78% effective in preventing mild cases of Covid-19 and 100% effective against severe and moderate infections.

Bloomberg News
The vaccine developed by China’s Sinovac Biotech Ltd. was found to be 78% effective against Covid-19 in late-stage trials in Brazil, the most definitive evidence so far on the shot’s efficacy after previous data sparked doubt and confusion.
 
The protection rate, confirmed by Sao Paulo state officials, was derived from Sinovac’s most advanced final-phase trials in Brazil involving about 13,000 participants. Coming after data was withheld at a progress update in late December, the rate is still below the roughly 95% effectiveness seen in cutting-edge mRNA vaccines developed by Pfizer Inc. and Moderna Inc. and being deployed in the U.S.

Sinovac’s

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in